Contraception with progestagens in systemic lupus erythematosus.
To test the efficacy and tolerance of progestagens as contraceptives in systemic lupus erythematosus (SLE), 200 mg IM norethisterone enanthate was administered to 10 patients, 0.03 mg/day oral levonorgestrel to 15 patients and they were compared with 18 control patients. There were 4 episodes of active SLE in 48 patient-months on norethisterone enantate and 6 episodes in 122 patient-months on levonorgestrel as compared with 9 episodes of active disease in 298 control patient-months (p = ns). There were no pregnancies and intermenstrual bleeding led to discontinuation of medication in 30% of patients. Progestagens may be an alternative contraceptive method in SLE.
D000328:Adult; D002986:Clinical Trials as Topic; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D016912:Levonorgestrel; D008180:Lupus Erythematosus, Systemic / Q000503:physiopathology*; D009640:Norethindrone / Q000008:administration & dosage* / Q000009:adverse effects; D009644:Norgestrel / Q000008:administration & dosage* / Q000009:adverse effects; D013237:Stereoisomerism
D003277:Contraceptives, Oral, Combined; D009644:Norgestrel; D016912:Levonorgestrel; D009640:Norethindrone